None listed
Conditions
Brief summary
To determine the interactions between lung disease, nocturnal sleep disordered breathing and daytime functioning in patients with cystic fibrosis. Overnight polysomnography will be compared with cough recordings and Sonomat recordings to evaluate sleep disruptions including cough, grunting, snores, shallow breathing and respiratory related arousals in cystic fibrosis patients. In addition, the study will evaluate if the sleep abnormalities, measured non-invasively, can predict the onset of a pulmonary exacerbation in a cystic fibrosis patient.
Interventions
For part 1 of the study, for one night, participants will perform:
1. an overnight polysomnography;
2. 24 hour cough recording;
3. sleep quality and quality of life questionnaires to measure sleep quality and overall quality of life;
4. Sonomat (a non-invasive recording device) recordings to validate the Sonomat measuring different aspects of sleep disordered breathing such as coughs, grunts, snores, shallow breathing and respiratory related arousals in cystic fibrosis.
For part 2 of the study
For part 1 of the study, for one night, participants will perform: 1. an overnight polysomnography; 2. 24 hour cough recording; 3. sleep quality and quality of life questionnaires to measure sleep quality and overall quality of life; 4. Sonomat (a non-invasive recording device) recordings to validate the Sonomat measuring different aspects of sleep disordered breathing such as coughs, grunts, snores, shallow breathing and respiratory related arousals in cystic fibrosis. For part 2 of the study, participants with use the Sonomat and cough recording device nightly for 3 months, or until they have had 2 exacerbations, to determine whether the Sonomat or cough recorder indicate the presence of a pulmonary exacerbation before it is noted clinically through daily diary cards and lung function measures.
Sponsors
Dr Odette Erskine
Eligibility
Sex/Gender
All
Age
17 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of cystic fibrosis 2. Clinically stable 3. Informed consent
Exclusion criteria
1. Inability to comply with protocol 2. Lack of informed consent 3. Clinical instability 4. Allergy to latex
Outcome results
None listed